SIGA Technologies CEO to Speak at NCT Asia Conference on October 23, 2019
October 21 2019 - 7:30AM
SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage
pharmaceutical company focused on the health security market, today
announced that Dr. Phillip L. Gomez, Chief Executive Officer, will
be a speaker at the Non-Conventional Threats (NCT) Asia Conference
in Kuala Lumpur, Malaysia.
Dr. Gomez will present on “Medical Preparedness
for Chemical, Biological, Radiological and Nuclear Defense (CBRNe)
Events” at 4:00 p.m. Malaysia Time on Wednesday, October 23, 2019.
He will be speaking at the conference in support of SIGA’s
collaboration with Meridian Medical Technologies, Inc. (a Pfizer
Company), with which SIGA announced an international promotion
agreement for TPOXX (tecovirimat) oral capsules in June 2019.
“We are pleased to have this opportunity to
share information about TPOXX and the role it might play in
effectively preparing for and responding to a smallpox outbreak
with Asian organizations focused on biopreparedness,” said Dr.
Gomez.
ABOUT SIGA TECHNOLOGIES, INC. and
TPOXX®
SIGA Technologies, Inc. is a commercial-stage
pharmaceutical company focused on the health security market.
Health security comprises countermeasures for biological, chemical,
radiological and nuclear attacks (biodefense market), vaccines and
therapies for emerging infectious diseases, and health
preparedness. Our lead product is TPOXX®, also known as tecovirimat
and ST-246®, an orally administered and intravenous (IV)
formulation antiviral medicine for the treatment of human smallpox
disease caused by variola virus. TPOXX is a novel small-molecule
drug and the US maintains a stockpile of 1.7 million courses in the
Strategic National Stockpile under Project BioShield. The FDA
approved the oral formulation of TPOXX for the treatment of
smallpox in July 2018. In September 2018, SIGA signed a new
contract with Biomedical Advanced Research and Development
Authority (BARDA) for procurement of oral and intravenous
formulations of TPOXX, and development activities. For more
information about SIGA, please visit www.siga.com.
About Smallpox1
Smallpox is a contagious, disfiguring and often
deadly disease that has affected humans for thousands of years.
Naturally occurring smallpox was eradicated worldwide by 1980, the
result of an unprecedented global immunization campaign. Samples of
smallpox virus have been kept for research purposes. This has led
to concerns that smallpox could someday be used as a biological
warfare agent. A vaccine can prevent smallpox, but the risk of the
current vaccine's side effects is too high to justify routine
vaccination for people at low risk of exposure to the smallpox
virus.
FORWARD-LOOKING STATEMENTS
This press release contains certain
“forward-looking statements” within the meaning of the Private
Securities Litigation Reform Act of 1995, as amended. Such
forward-looking statements are subject to various known and unknown
risks and uncertainties, and SIGA cautions you that any
forward-looking information provided by or on behalf
of SIGA is not a guarantee of future performance. More
detailed information about SIGA and risk factors that may
affect the realization of forward-looking statements, including the
forward-looking statements in this press release, is set forth
in SIGA’s filings with the Securities and Exchange
Commission, including SIGA’s Annual Report on Form 10-K
for the fiscal year ended December 31, 2018, and in other
documents that SIGA has filed with
the SEC. SIGA urges investors and security holders
to read those documents free of charge at the SEC's web
site at http://www.sec.gov. Interested parties may also obtain
those documents free of charge from SIGA. Forward-looking
statements are current only as of the date on which such statements
were made, and except for our ongoing obligations under the
United States of America federal securities laws, we undertake no
obligation to update publicly any forward-looking statements
whether as a result of new information, future events, or
otherwise.
Contacts:
InvestorsDavid Carey
212-867-1768david.carey@finnpartners.com
MediaStephanie
Seiler206-713-0124stephanie.seiler@finnpartners.com
1
http://www.mayoclinic.org/diseases-conditions/smallpox/basics/definition/con-20022769
SIGA Technologies (NASDAQ:SIGA)
Historical Stock Chart
From Mar 2024 to Apr 2024
SIGA Technologies (NASDAQ:SIGA)
Historical Stock Chart
From Apr 2023 to Apr 2024